This article is more than 5 years old. Information may no longer be current.
Top pulmonology news from October: ERS International Congress coverage, effects of e-cigarettes and more
Click Here to Manage Email Alerts
Healio Pulmonology has you covered. The Editors have compiled a list of popular articles posted on Healio Pulmonology in October.
See below for links to studies on new treatments for interstitial lung disease presented at the European Respiratory Society International Congress, FDA approvals and rejections, updates on the outbreak of electronic cigarette-related lung injuries and more.
Triple therapy approved to treat cystic fibrosis
The FDA announced it has approved elexacaftor/ivacaftor/tezacaftor, the first triple combination therapy for patients with the most common cystic fibrosis mutation. Read more
CDC provides update on vaping-related injuries
As of Oct. 8, 1,299 confirmed and probable cases of lung injury associated with electronic cigarette use, or vaping, have been reported by 49 states, the District of Columbia and the U.S. Virgin Islands. There have also been 26 deaths confirmed and reported to CDC from 21 states, including a death in a patient aged only 17 years, Anne Schuchat, MD, CDC principal deputy director, said during a telebriefing.
E-cigarette flavor may affect asthma pathophysiology
The effect of electronic cigarettes without nicotine on allergic airway disease may depend on flavor, which suggests that some flavored e-cigarettes may alter the pathophysiology of asthma, a recent study on mice suggests. Read more
Occupational exposure to disinfectants may raise COPD risk
New data published in JAMA Network Open showed that the risk for COPD incidence was higher among nurses who regularly performed cleaning and disinfectant tasks. Read more
Stone fabrication workers at risk for silicosis
Eighteen cases of silicosis in stone fabrication workers have highlighted the occupational risk faced by those who work with engineered stone, according to findings published in Morbidity and Mortality Weekly Report. Read more
Triple therapy fails to win FDA approval for COPD
The FDA has issued a complete response letter regarding the new drug application for PT010 — an inhaled triple-combination therapy — for COPD, according to a press release from the manufacturer. Read more
INBUILD: Nintedanib slows progression of fibrosing ILD
When compared with placebo, nintedanib slowed the annual rate of decline in FVC in patients with progressive fibrosing interstitial lung disease other than idiopathic pulmonary fibrosis, researchers reported at the European Respiratory Society International Congress. Read more
Pamrevlumab may be safe, effective in IPF
In a phase 2 trial, pamrevlumab, a fully recombinant human monoclonal antibody against connective tissue growth factor, appeared to reduce the decline in lung function among patients with idiopathic pulmonary fibrosis. Read more
Pirfenidone promising for unclassifiable ILD
Pirfenidone treatment was associated with improvement in several outcomes among patients with progressive fibrosing unclassifiable interstitial lung disease, according to a new study. Read more
Three-in-one asthma inhaler may improve lung function, reduce exacerbations
The addition of a long-acting muscarinic antagonist to inhaled corticosteroid plus long-acting beta-2 agonist therapy in a single inhaler improves lung function and reduces exacerbations among patients with uncontrolled asthma, according to data from two phase 3 studies presented at the European Respiratory Society International Congress. Read more